Andrew M Kaunitz1, David Portman2, Carolyn L Westhoff3, David F Archer4, Daniel R Mishell5, Marie Foegh6. 1. Department of Obstetrics and Gynecology, University of Florida College of Medicine, Jacksonville, 653-1 West 8th Street, Jacksonville, FL 32209, USA. Electronic address: andrew.kaunitz@jax.ufl.edu. 2. Columbus Center for Women's Health Research, 99 Brice Road North, Columbus, OH 43213, USA. 3. Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA. 4. Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA. 5. Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, 2020 Zonal Avenue, Room 220, Los Angeles, CA 90033, USA. 6. Department of Pharmacology, New York Medical College, Basic Science Building, 15 Dana Road, Valhalla, NY 10595, USA.
Abstract
OBJECTIVE:Pregnancy rates in US contraceptive clinical trials are increasing due to decreased treatment compliance. This study compared compliance with a new low-dose levonorgestrel (LNG) and ethinyl estradiol (EE) contraceptive patch (CP, Twirla™) with that of a low-dose combination oral contraceptive (COC) in a demographically diverse population. STUDY DESIGN: This analysis was part of an open-label, parallel-group, multicenter phase 3 study that randomized healthy sexually active women (17-40years) to 13cycles of LNG/EE CP or 6cycles of COC, then 7cycles of LNG/EE CP. We defined self-reported compliance as cycles that, according to diaries, show 21days of patch wear without missed days or any patch worn >7days or 21days of pill-taking without missed pill days. We verified compliance by detectable plasma presence of LNG and EE at cycles 2, 6, and 13. RESULTS: Of the intention-to-treat population with diary information (N=1328, mean age 26.4years, 46% minorities, 33% obese), 10.0% of the CP (n=998) versus 21.2% of the COC group (n=330) self-reported noncompliance after 6cycles (p<.001). Laboratory assessments verified 10-14% of participants in both groups as noncompliant. Self-reported perfect use did not vary between obese [body mass index (BMI) ≥30kg/m(2)] versus nonobese (BMI <30kg/m(2)) participants in both groups or when stratified by age, education, or race/ethnicity in the CP group. CONCLUSIONS:Self-reported compliance was significantly greater in the CP than COC group and did not vary by obesity status. Discrepancies between self-reported and verified compliance question reliability of patient diaries. IMPLICATIONS STATEMENT: This paper, based on an analysis of a phase 3 trial, shows that compliance was significantly greater with a new weekly transdermal CP than with a once-daily COC in obese as well as nonobese participants. Discrepancies between self-reported compliance and laboratory-verified compliance raise questions regarding the reliability of patient diaries.
RCT Entities:
OBJECTIVE: Pregnancy rates in US contraceptive clinical trials are increasing due to decreased treatment compliance. This study compared compliance with a new low-dose levonorgestrel (LNG) and ethinyl estradiol (EE) contraceptive patch (CP, Twirla™) with that of a low-dose combination oral contraceptive (COC) in a demographically diverse population. STUDY DESIGN: This analysis was part of an open-label, parallel-group, multicenter phase 3 study that randomized healthy sexually active women (17-40years) to 13cycles of LNG/EE CP or 6cycles of COC, then 7cycles of LNG/EE CP. We defined self-reported compliance as cycles that, according to diaries, show 21days of patch wear without missed days or any patch worn >7days or 21days of pill-taking without missed pill days. We verified compliance by detectable plasma presence of LNG and EE at cycles 2, 6, and 13. RESULTS: Of the intention-to-treat population with diary information (N=1328, mean age 26.4years, 46% minorities, 33% obese), 10.0% of the CP (n=998) versus 21.2% of the COC group (n=330) self-reported noncompliance after 6cycles (p<.001). Laboratory assessments verified 10-14% of participants in both groups as noncompliant. Self-reported perfect use did not vary between obese [body mass index (BMI) ≥30kg/m(2)] versus nonobese (BMI <30kg/m(2)) participants in both groups or when stratified by age, education, or race/ethnicity in the CP group. CONCLUSIONS: Self-reported compliance was significantly greater in the CP than COC group and did not vary by obesity status. Discrepancies between self-reported and verified compliance question reliability of patient diaries. IMPLICATIONS STATEMENT: This paper, based on an analysis of a phase 3 trial, shows that compliance was significantly greater with a new weekly transdermal CP than with a once-daily COC in obese as well as nonobese participants. Discrepancies between self-reported compliance and laboratory-verified compliance raise questions regarding the reliability of patient diaries.
Authors: Maria Pyra; Jairam R Lingappa; Renee Heffron; David W Erikson; Steven W Blue; Rena C Patel; Kavita Nanda; Helen Rees; Nelly R Mugo; Nicole L Davis; Athena P Kourtis; Jared M Baeten Journal: Contraception Date: 2018-02-17 Impact factor: 3.375
Authors: Laureen M Lopez; Alissa Bernholc; Mario Chen; Thomas W Grey; Conrad Otterness; Carolyn Westhoff; Alison Edelman; Frans M Helmerhorst Journal: Cochrane Database Syst Rev Date: 2016-08-18
Authors: Sharon L Achilles; Michele N Austin; Leslie A Meyn; Felix Mhlanga; Zvavahera M Chirenje; Sharon L Hillier Journal: Am J Obstet Gynecol Date: 2018-03-02 Impact factor: 8.661
Authors: S Husain; J Allotey; Z Drymoussi; M Wilks; B M Fernandez-Felix; A Whiley; J Dodds; S Thangaratinam; C McCourt; E M Prosdocimi; W G Wade; B M de Tejada; J Zamora; K Khan; M Millar Journal: BJOG Date: 2019-04-01 Impact factor: 6.531
Authors: Sharon L Achilles; Felix G Mhlanga; Petina Musara; Samuel M Poloyac; Zvavahera M Chirenje; Sharon L Hillier Journal: Contraception Date: 2017-09-28 Impact factor: 3.375